Further d etails of sample collection, processing, and shipment will be provided in the Laboratory Manual. Revised Protocol No.: 04 Date: 31-May-2019 109 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Table 9.5-1: Pharmacokinetic and Immunogenicity Sampling Schedule for BMS-986226 (Pr eliminary Safety Cohorts and Part A) Study Day of Sample Collection (1 Cycle = 4 Weeks)EventTime (Relative to Start of BMS-986226 Infusion) Hour:MinBMS-986226 Blood SampleBMS-986226 Immunogenicity Sample Treatment Cycles Cycle 1 Day 1 (C1D1)aPre-dose 0:00 X X EOIb0:30 X 4:00 X C1D2 24:00 X C1D4 72:00 X C1D8 (+/- 1 day) 168:00 X C1D15 (+/- 1 day) 336:00 X X C1D22 (+/- 1 day) 504:00 X C2D1Pre-dose 0:00 X X EOIb0:30 X 4:00 X C2D2 24:00 X C2D8 (+/- 1 day) 168:00 X C2D15 (+/- 1 day) 336:00 X C2D22 (+/- 1 day) 504:00 X C3D1Pre-dose 0:00 X X EOIb0:30 X C3D2 24:00 X Revised Protocol No.: 04 Date: 31-May-2019 110 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Table 9.5-1: Pharmacokinetic and Immunogenicity Sampling Schedule for BMS-986226 (Pr eliminary Safety Cohorts and Part A) Study Day of Sample Collection (1 Cycle = 4 Weeks)EventTime (Relative to Start of BMS-986226 Infusion) Hour:MinBMS-986226 Blood SampleBMS-986226 Immunogenicity Sample C3D8 (+/- 1 day) 168:00 X C3D15 (+/- 1 day) 336:00 X C3D22 (+/- 1 day) 504:00 X C4D1Pre-dose 0:00 X X EOIb0:30 X C5D1 Pre-dose 0:00 X X C6D1 Pre-dose 0:00 X X Adverse Event Grade 3/4 Hypersensitivity Reactionc X X End of Treatment and Follow-up Period EOT X X 30-Day FU X X 60-Day FU X X 100-Day FU X X aParticipants taking 2 or 8 mg of BMS-986226 in the Pr eliminary Saf ety Cohorts w ill follow the same sampling schedule as in Par t A. In the event that participants taking 2 or 8 mg of BMS-986226 should be permitted to intra-dos e escalate up to 8 and/or 25 mg, the sampling schedule should be restarted at Cycle 1 Day 1 at each dose escalation. bThis sample should be taken immediately prior to the stopping of the BMS -986226 drug i nfusion (in monotherapy), preferably within 2 minutes prior to the end of infusion. If the end of infusion is delayed beyond the nomin al infusion duration, the collection of this sample should also b e delayed accordingly. EOI samples may not be collected from the same IV access as the drug was administered. Revised Protocol No.: 04 Date: 31-May-2019 111 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS cSamples will be taken as directed when drug-related adverse event, Grade 3/4 infusion reaction, or hypersensitivity reaction is confirmed. Abbreviations: C = Cycle; D = Day; EOI = end of infusion; EOT = end of treatment; FU = follow-up. Revised Protocol No.: 04 Date: 31-May-2019 112 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Table 9.5-2: Pharmacokinetic and Immunogenicity Sampling Schedule for BMS-986226 (Parts B1 and C1) Study Day of Sample Collection(Cycle = 4 weeks)EventTime (Relative to Start of Nivolumab or Ipilimumab Infusion) Hour:MinBMS-986226 Blood SampleBMS-986226 Immunogenicity Sample Treatment Cycles Cycle 1 Day 1 (C1D1)Pre-dosea00:00 X X EOIb00:30 X 04:00 X C1D2 24:00 X C1D4 72:00 X C1D8 (+/- 1 day) 168:00 X C1D15 (+/- 1 day) 336:00 X C1D22 (+/- 1 day) 504:00 X C2D1 Pre-dose 0:00:00 X X C2D8 (+/- 1 day) 168:00 X C2D15 (+/- 1 day) 336:00 X C3D1 Pre-dose 0:00 X X C4D1Pre-dose 0:00 X X EOIb0:30 X 4:00 X C4D2 24:00 X C4D8 (+/- 1 day) 168:00:00 X C4D15 (+/- 1 day) 336:00:00 X Revised Protocol No.: 04 Date: 31-May-2019 113 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Table 9.5-2: Pharmacokinetic and Immunogenicity Sampling Schedule for BMS-986226 (Parts B1 and C1) Study Day of Sample Collection(Cycle = 4 weeks)EventTime (Relative to Start of Nivolumab or Ipilimumab Infusion) Hour:MinBMS-986226 Blood SampleBMS-986226 Immunogenicity Sample C4D22 (+/- 1 day) 504:00:00 X C5D1 Pre-dose 0:00 X C5D8 (+/- 1 day) 168:00 X C5D15 (+/- 1 day) 336:00 X C6D1 Pre-dose 0:00 X X C7D1 Pre-dose 0:00 X X C7D1 EOIb0:30 X C8D1 Pre-dose 0:00 X C10D1Pre-dose 0:00 X X EOIb0:30 X Every 3 Cycles starting with C13D1 (example: C16D1, C19D1, etc)Pre-dose 0:00 X X Adverse Event Grade 3/4 Hypersensitivity ReactioncX End of Treatment and Follow-up Period EOT X X 30-Day FU X X Revised Protocol No.: 04 Date: 31-May-2019 114 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Table 9.5-2: Pharmacokinetic and Immunogenicity Sampling Schedule for BMS-986226 (Parts B1 and C1) Study Day of Sample Collection(Cycle = 4 weeks)EventTime (Relative to Start of Nivolumab or Ipilimumab Infusion) Hour:MinBMS-986226 Blood SampleBMS-986226 Immunogenicity Sample 60-Day FU X X 100-Day FU X X aAll pre-dose samples for BMS-986226 should be taken prior to the start of nivolumab/ipilimu mab infusion (preferably within 30 minutes). bThis sample should be taken immediately prior to the stopping of the second drug infusion (in combination therapy), prefera bly within 2 minutes prior to the end of infusion.